FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:967-968 September 28, 2000 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Herrmann, H. C. PubMed Citation

To the Editor: Herrmann et al. (June 1 issue)¹ concluded that "oral sildenafil has no direct adverse cardiovascular effects in men with severe coronary artery disease." However, they studied only a single dose of sildenafil in only 14 men, in an open-label study with no controls that was conducted after the administration of diphenhydramine and diazepam — drugs not normally used in conjunction with sildenafil for its only indication, erectile dysfunction. Moreover, there was no adjustment for the various other medications the men were taking (beta-blockers, aspirin, heparin, and angiotensin-converting–enzyme inhibitors). In this context, the authors' conclusion is overly strong.

. . . [Full Text of this Article]

References

This article has been cited by other articles:

• DeBusk, R. F., Malozowski, S., Sahlroot, J. T., Pellikka, P. A., Arruda-Olson, A. M. (2002). Sildenafil and Physical Exertion in Men With Coronary Artery Disease. JAMA 287: 2359-2360 [Full Text]  
• Young, T., Peppard, P. E., Gottlieb, D. J. (2002). Epidemiology of Obstructive Sleep Apnea: A Population Health Perspective. Am. J. Respir. Crit. Care Med. 165: 1217-1239 [Abstract] [Full Text]